The results of a recent clinical trial (NCT03743766) published in Cell might pave the way for significant advances in treating advanced melanoma , a serious form of skin cancer. The study, led by University of Pittsburgh and UPMC Hillman Cancer…
We are pleased to share that Jeremy Rich, MD, MHS, MBA, deputy director, UPMC Hillman Cancer Center, has been selected and agreed to serve as interim director, effective Aug. 7, to see us through the transition period with Robert Ferris, MD,…
Please join us in welcoming Michelle Williams, PhD, to UPMC Hillman Cancer Center, effective May 1, 2024. Dr. Williams is Assistant Professor in the Department of Pharmacology and Chemical Biology at the University of Pittsburgh. Dr. Williams will develop an…
Please join us in welcoming Devanjan “Dev” Sikder, DVM, PhD to UPMC Hillman Cancer Center, effective July 1, 2024. Dr Sikder is Associate Professor in the Department of Medicine, Division of Malignant Hematology/Oncology at the University of Pittsburgh and Director…
Jeffrey Brodsky, PhD, Yuan Chang, MD, and Patrick Moore, MD, MPH, faculty of UPMC Hillman Cancer Center and professors of the University of Pittsburgh, were announced as members to the American Academy of Arts and Sciences. The Academy is a…
Bennett Van Houten, PhD, co-director of the Genome Stability Program at UPMC Hillman Cancer Center, and Richard M. Cyert Professor of Molecular Oncology and professor of pharmacology and chemical biology in the University of Pittsburgh School of Medicine, is among…
Norman Wolmark, MD, received the Medallion for the Advancement of Surgical Care from the American Surgical Association this month. The American Surgical Association is our nation’s oldest and most prestigious surgical association. Dr. Wolmark has contributed to some of the…
Please join us in welcoming Marija Balic, MD, ScD, MBA to UPMC Hillman Cancer Center, effective March 1, 2024 as professor in the Department of Medicine, Division of Hematology/Oncology at the University of Pittsburgh. Dr. Balic will provide three half days…
Researchers from UPMC Hillman Cancer Center and colleagues published their results from the CAMILLA trial showing that combining cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer is a promising treatment, potentially expanding treatment options for patients with microsatellite stable…
Please join UPMC Hillman Cancer Center in welcoming Saad Sheikh, MD, effective February 1, 2024. Dr. Sheikh is an assistant professor in the Department of Radiation Oncology at the University of Pittsburgh and a member of the Genome Stability Program…
